Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion

被引:44
作者
Dammann, HG [1 ]
Burkhardt, F [1 ]
机构
[1] Wissensch Inst, Klin Forsch Hamburg, D-20249 Hamburg, Germany
关键词
meal-stimulated gastric acid secretion; omperazole; pantoprazole;
D O I
10.1097/00042737-199911000-00016
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aims To determine the influence of recommended therapeutic doses of pantoprazole and omeprazole on meal-stimulated acid secretion. Methods In this double-blind, placebo-controlled, three-period crossover study, 12 healthy male volunteers received 40 mg pantoprazole od, 20 mg omeprazole od or placebo at 08:00 h for 5 days in a randomized order. Meal-stimulated acid secretion was determined by means of a homogenized test meal, and intragastric titration on day 1, 4-6 h, 8-10 h, 16-18 h, and 24-26 h, and on days 3 and 5, 4-6 h after oral drug administration. Results On day 1 (4-6 h after oral drug administration), meal-stimulated acid secretion was decreased by 36% and 24% after administration of 40 mg pantoprazole or 20 mg omeprazole, respectively. After 3 and 5 days of dosing, the decreases were 88% and 85% with 40 mg pantoprazole, and 70% and 74% with 20 mg omeprazole. At all measuring points during the 5-day dosing periods, 40 mg pantoprazole proved superior to 20 mg omeprazole in inhibiting meal-stimulated gastric acid secretion. The differences were statistically significant for pantoprazole on day 1,24-26 h after oral drug administration and on day 3 (P = 0.0425 and P = 0.0244, respectively). On day 1, only pantoprazole was significantly better than placebo (P = 0.0210, 4-6 h after dosing; P = 0.0093, 8-10 h after dosing and P = 0.0068, 16-18 h after dosing). Conclusion Pantoprazole 40 mg is significantly more effective than omeprazole 20 mg in inhibiting meal-stimulated acid secretion, in addition, pantoprazole exhibits a more rapid onset of action. Eur J Gastroenterol Hepatol 11:1277-1282 (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:1277 / 1282
页数:6
相关论文
共 46 条
[31]  
SACHS G, 1995, ANNU REV PHARMACOL, V35, P277, DOI 10.1146/annurev.pa.35.040195.001425
[32]  
SHARMA B, 1987, Alimentary Pharmacology and Therapeutics, V1, P67
[33]   OPTIMAL DOSE OF ORAL OMEPRAZOLE FOR MAXIMAL 24 HOUR DECREASE OF INTRAGASTRIC ACIDITY [J].
SHARMA, BK ;
WALT, RP ;
POUNDER, RE ;
GOMES, MDA ;
WOOD, EC ;
LOGAN, LH .
GUT, 1984, 25 (09) :957-964
[34]  
SIMON A, 1993, GASTROENTEROLOGY, V104, pA192
[35]  
SIMON B, 1990, ALIMENT PHARM THERAP, V4, P373
[36]   BY 1023/SK-AND-F 96022 - BIOCHEMISTRY OF A NOVEL (H+ + K+)-ATPASE INHIBITOR [J].
SIMON, WA ;
KEELING, DJ ;
LAING, SM ;
FALLOWFIELD, C ;
TAYLOR, AG .
BIOCHEMICAL PHARMACOLOGY, 1990, 39 (11) :1799-1806
[37]   THE H+,K+-ATPASE INHIBITOR PANTOPRAZOLE (BY1023/SK-AND-F96022) INTERACTS LESS WITH CYTOCHROME-P450 THAN OMEPRAZOLE AND LANSOPRAZOLE [J].
SIMON, WA ;
BUDINGEN, C ;
FAHR, S ;
KINDER, B ;
KOSKE, M .
BIOCHEMICAL PHARMACOLOGY, 1991, 42 (02) :347-355
[38]  
SIMON WA, 1991, ARCH PHARM, V343, pA295
[39]  
STEINIJANS VW, 1996, INT J CLIN PHARM S1, V34, P531
[40]  
TUCKER GT, 1994, ALIMENT PHARM THERAP, V8, P33